Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Immunitybio Inc (NQ: IBRX )

6.664 -0.376 (-5.34%)
Streaming Delayed Price Updated: 12:43 PM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Immunitybio Inc

< Previous 1 2 3 4 5 Next >
IBRX SHAREHOLDER ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
INVESTOR ACTION ALERT: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against ImmunityBio, Inc. (NASDAQ: IBRX); Lead Plaintiff Deadline is August 29, 2023
From Scott+Scott Attorneys at Law LLP
Via Business Wire
ImmunityBio, Inc. (IBRX) Stock News: Investors with Large Losses Should Contact Robbins LLP Regarding ImmunityBio, Inc. Class Action
From Robbins LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)
From Law Offices of Howard G. Smith
Via Business Wire
IMMUNITYBIO, INC. (NASDAQ: IBRX) SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against ImmunityBio, Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, A LONGSTANDING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. (IBRX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients
From ImmunityBio, Inc.
Via Business Wire
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of ImmunityBio, Inc. (IBRX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Calling All ImmunityBio, Inc. (IBRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC Today!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IBRX
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
Calling All ImmunityBio, Inc. (IBRX) Investors: Contact Bronstein, Gewirtz & Grossman, LLC Today!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
SHAREHOLDER ACTION REMINDER: Scott+Scott Attorneys at Law LLP Reminds Investors That a Securities Class Action Has Been Filed Against ImmunityBio, Inc. (NASDAQ: IBRX); Lead Plaintiff Deadline is August 29, 2023
From Scott+Scott Attorneys at Law LLP
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arrow and ImmunityBio and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of ImmunityBio, Inc. (IBRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of ImmunityBio, Inc. (IBRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
IMMUNITYBIO, INC. SHAREHOLDER ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (NASDAQ: IBRX)
From Bernstein Liebhard LLP
Via GlobeNewswire
EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – IBRX
From The Rosen Law Firm, P.A.
Via Business Wire
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against ImmunityBio, Inc. (IBRX)
From Robbins LLP
Via Business Wire
ImmunityBio to Participate in the Jefferies Global Healthcare Conference
From ImmunityBio, Inc.
Via Business Wire
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ImmunityBio, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ImmunityBio Inc. (IBRX) Investigation
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
National Multicenter Trial Opens to Study ImmunityBio’s Tri-Ad5 Cancer Vaccines Plus N-803 to Prevent Cancer in People with Lynch Syndrome
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Executive Chairman Dr. Patrick Soon-Shiong Delivers the Packard Lecture at Uniformed Services University
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio to Present ‘Quality of life in QUILT 3.032 study: Patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving IL-15R⍺Fc superagonist N-803 plus BCG’ at ASCO GU
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Execution of $50 Million Equity Financing with Multiple Institutional Investors
From ImmunityBio, Inc.
Via Business Wire
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
From ImmunityBio, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.